Telomir regains Nasdaq compliance on annual meeting requirement

Telomir Pharmaceuticals, Inc.

Received letter from Nasdaq on March 30, 2026 confirming compliance with Rule 5620(a).
Compliance achieved after holding the 2025 Annual Meeting of Shareholders.
Nasdaq has determined the matter closed.
No further actions required from the company regarding this deficiency.

item 8.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.